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Blood Pressure Lowering Treatment Trialists’ CollaborationMObjectives To evaluate the blood pressure-dependent and
independent effects of angiotensin-converting enzyme
inhibitors (ACEI) and angiotensin receptor blockers (ARB)
on major cardiovascular events.
Methods Using data from 26 large-scale trials comparing
an ACEI or an ARB with placebo or another drug class, meta-
regression analyses were conducted in which treatment-
specific relative risks for major cause-specific outcomes
[stroke, major coronary heart disease (CHD) events and
heart failure] were regressed against follow-up blood
pressure differences.
Results From a total of 146 838 individuals with high blood
pressure or an elevated risk of cardiovascular disease,
22 666 major cardiovascular events were documented
during follow-up. The analyses showed comparable blood
pressure-dependent reductions in risk with ACEI and ARB
(P >– 0.3 for all three outcomes). The analyses also showed
that ACEI produced a blood pressure-independent
reduction in the relative risk of CHD of approximately 9%
(95% confidence interval 3–14%). No similar effect was
detected for ARB, and there was some evidence of aopyright © Lippincott Williams & Wilkins. Unauth
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0263-6352  2007 Lippincott Williams & Wilkinsdifference between ACEI and ARB in this regard (P U 0.002).
For both stroke and heart failure there was no evidence of
any blood pressure-independent effects of either ACEI or
ARB.
Conclusion There are similar blood pressure-dependent
effects of ACEI and ARB for the risks of stroke, CHD and
heart failure. For ACEI, but not ARB, there is evidence of
blood pressure-independent effects on the risk of major
coronary disease events. J Hypertens 25:951–958 Q 2007
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It is well established that the risks of major cardiovascular
events are reduced by a broad range of blood pressure-
lowering drugs, including angiotensin-converting enzyme
inhibitors (ACEI) and angiotensin receptor blockers
(ARB) [1]. Analyses by the Blood Pressure Lowering
Treatment Trialists’ Collaboration (BPLTTC) have
shown that the size of the blood pressure reduction is
an important determinant of the size of these treatment
effects. It remains uncertain, however, whether mechan-
isms independent of blood pressure also affect the size of
the treatment benefit [2–7]. Agents acting via the renin–
angiotensin system have received special attention in
this regard, but there have been few formal attempts to
investigate any such class-specific effects. Using data from
26 trials of ACEI or ARB that were eligible for inclusion
in the BPLTTC overviews, we conducted analyses to
determine the relative contribution of blood pressure-
dependent and independent mechanisms to the
reductions in risk of major cardiovascular events produced
by these inhibitors of the renin–angiotensin system.Methods
Analyses were designed and conducted by the members
of the Blood Pressure Lowering Treatment Trialists’
Collaboration (the Collaboration). The primary aim of
this Collaboration is the conduct of prospectively planned
overviews (meta-analyses) of randomized trials of differ-
ent blood pressure-lowering regimens on major cardio-
vascular events [8] among patients with high blood
pressure, diabetes, a history of coronary heart disease
(CHD) or cerebrovascular disease.
Trials included
Trials already participating in the Collaboration that had
a treatment group assigned to an ACEI or an ARB, and
with results published by the end of 2004, were included
in these analyses [6,7,9–32]. These trials fall into three
broad groups: trials with a placebo comparator; trials with
a ‘conventional’ therapy (a diuretic or beta-blocker)
comparator; and trials with a calcium antagonist compa-
rator. Two potentially eligible ACEI trials were not
included because data were unavailable [33,34]. When
a trial included more than two treatment armsorized reproduction of this article is prohibited.
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sons were calculated except when early termination of
one arm made such estimates infeasible [35,36].
None of the completed BPLTTC trials has involved
direct head-to-head comparisons of an ACEI and an
ARB. Such comparisons have, however, been undertaken
in other completed trials, mainly among patients with
heart failure or acute myocardial infarction [3,4,37]. We
therefore sought data on the same primary study out-
comes from all these trials that otherwise met the
inclusion criteria listed in the original Collaboration
protocol [8]. Data from these non-BPLTTC trials are
reported here in supplementary meta-analyses to assist in
the interpretation of findings from the primary analyses.
Outcomes
The primary outcomes for these analyses were: (i) non-
fatal stroke or death from cerebrovascular disease; (ii)
non-fatal myocardial infarction or death from CHD,
including sudden death; (iii) heart failure causing death
or requiring hospitalization.
Blood pressure reductions and risk reductions
Blood pressure differences during follow-up
For each trial, the mean difference in follow-up systolic
blood pressure levels between the randomized groups
was sought. Whenever possible, this difference was
calculated using all available follow-up blood pressure
measurements, weighted by the time since the last
measurement. The blood pressure difference was
assigned a negative value when the follow-up blood
pressure level was lower in the first listed agent compared
with the second listed agent (see Table 1 for format).
Risk reductions
The logarithm of the odds ratio and relative risk and their
variance were calculated for each trial and for each out-
come according to the principle of intention to treat. An
odds ratio or relative risk of less than one indicates
that the risk of the relevant outcome was lower in
the first listed agent compared with the second listed
agent. Percentage reductions in risk were estimated as
[(1OR) 100], where OR is the odds ratio.
Statistical analyses
In the primary analysis of data from the 26 trials compar-
ing an ACEI or ARB against placebo or another drug
class, the association between the difference in follow-up
systolic blood pressure levels and the log odds ratio for
each of the three outcomes was investigated using
random effects meta-regression analysis with inverse
variance weighting [38]. Analyses were carried out using
the metareg routine in STATA (release 8.0; Stata
Corporation, College Station, Texas, USA). Standard
methods for the comparison of regression models were
used [38]. Initially, using a single regression model,opyright © Lippincott Williams & Wilkins. Unauthoseparate regression lines were fitted for trials in which
ACEI were the investigational treatment and in which
ARB were the investigational treatment. For each out-
come, the slopes of these lines were compared, so as to
test for a differential effect of blood pressure reduction on
risk in trials of ACEI compared with ARB. If these slopes
were not significantly different (P> 0.05), a parallel
lines regression model was fitted, which assumes equal
effects of blood pressure reduction with ACEI and ARB.
Using this model, the null hypothesis of no separation
between the two parallel lines was tested to explore
whether there was evidence of a differential effect of
the two drug classes independent of blood pressure low-
ering. Assumptions of linear associations between differ-
ences in follow-up blood pressure levels and log odds
ratios were tested using standard graphical methods
[38]. The intercept of each regression line, a, estimates
the value of the log odds ratio when the difference in
blood pressure reduction is zero. The slope, b, of each
regression line estimates the log odds ratio for a unit
change in follow-up systolic blood pressure difference.
Both were reported with 95% confidence intervals.
Previous reports from the Collaboration [1] provided clear
evidence that regimens based on calcium antagonists,
compared with those based on ACEI and diuretics/
beta-blockers, provide significantly less protection
against hospitalized or fatal heart failure. This effect
was independent of differences in achieved blood pres-
sure reduction, and, for this reason, trials with calcium
antagonist comparator arms were excluded from the
primary analyses of heart failure in this study. To check
the validity of this assumption, however, and to test
whether the main results were dependent upon other
comparator treatments, a series of sensitivity analyses
were performed. The heart failure analyses were
repeated including the trials with calcium antagonist
comparator arms; the stroke and CHD analyses were
repeated after the exclusion of trials with calcium
antagonist comparator arms; and, for all outcomes,
analyses were repeated after excluding trials with diure-
tic/beta-blocker comparator arms.
In the supplementary meta-analyses of data from the
three trials [3,4,37] in which there was a direct random-
ized comparison of an ACEI and an ARB, overall esti-
mates of relative risk and 95% confidence intervals were
calculated for stroke, CHD and heart failure using a
random effects model [38].
Results
There were 17 ACEI trials involving 101 626 individuals,
and nine ARB trials involving 45 212 individuals
(Table 1). Overall, a total of 22 666 events (6419 stroke,
9048 CHD and 7199 heart failure) were included. The
mean age of individuals in the ACEI trials was 65 years, of
whom 61% were men. In the ARB trials, the mean age ofrized reproduction of this article is prohibited.
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Table 1 Characteristics of trials included by randomized comparison
Comparison Trial
No. randomly
assigned to relevant
comparison
SBP difference
between randomized
groupsb
Odds ratio (95% CI)
Stroke CHD Serious heart failure
ACEI trials
ACEI versus placebo
CAMELOT 1332 5.6 0.65 (0.3–1.6) 0.56 (0.3–1.2)d 0.78 (0.2–2.9)
DIAB–HYCAR 4912 1.8 1.03 (0.8–1.3) 0.79 (0.6–1.1) 0.84 (0.6–1.1)
EUROPA 12 218 4.6 0.96 (0.7–1.3) 0.75 (0.6–0.9)g 0.61 (0.4–0.8)
HOPE 9297 2.9 0.68 (0.6–0.8) 0.79 (0.7–0.9) 0.85 (0.7–1.1)
PART2 617 6.0 1.77 (0.5–6.1) 0.66 (0.4–1.1) 0.70 (0.3–1.9)
PEACE 8290 3.0 0.76 (0.6–1.0) 1.00 (0.8–1.2)d 0.74 (0.6–1.1)
PROGRESSa 2561 4.9 0.94 (0.7–1.2) 0.98 (0.7–1.4) 0.92 (0.6–1.5)
SCAT 460 3.5 0.22 (0.0–1.0) 0.61 (0.2–1.5) 0.20 (0.0–1.8)
ACEI versus diuretic/beta-blocker
AASK 877 1.0 1.01 (0.6–1.08) NA 0.92 (0.5–1.7)
ALLHAT 24 309 2.5 1.15 (1.0–1.3) 0.99 (0.9–1.1) 1.10 (0.9–1.3)
ANBP2 6083 1.2 1.05 (0.8–1.4) 0.70 (0.5–1.0) 0.94 (0.6–1.4)
CAPPP 10 985 0.3 1.29 (1.0–1.6) 0.96 (0.8–1.2) NA
STOP2 4418 2.1 0.90 (0.7–1.1) 0.98 (0.8–1.3) 1.78 (0.8–3.8)
UKPDS 758 1.2 1.11 (0.6–2.1) 1.22 (0.8–1.8) 0.89 (0.3–2.6)
ACEI versus calcium antagonist
ABCD (H) 470 2.8 0.70 (0.3–1.6) 0.40 (0.2–0.8) 1.32 (0.5–3.3)
ABCD (N) 480 2.4 0.56 (0.2–1.6) 0.84 (0.4–1.6) 1.04 (0.4–2.4)
ALLHAT 18 102 1.3 1.22 (1.0–1.4) 1.00 (0.9–1.1) 0.80 (0.7–0.9)
CAMELOT 1340 0.1 1.32 (0.5–3.8) 0.77 (0.3–1.7) 1.32 (0.3–5.9)
JMIC–B 1650 3.7 1.07 (0.5–2.1) 0.79 (0.4–1.5) 0.84 (0.4–1.9)
STOP2 4401 0.6 1.04 (0.8–1.3) 0.86 (0.7–1.1) 1.44 (0.7–3.0)i
ARB trials
ARB versus placebo
CHARM–Added 2548 2.5 1.15 (0.8–1.8) 0.62 (0.4–0.9)e 0.82 (0.7–1.0)
CHARM–Alternative 2028 2.1 0.85 (0.5–1.3) 1.61 (1.1–2.3)e 0.66 (0.5–0.8)
CHARM–Preserved 3023 2.9 0.91 (0.6–1.3) 0.77 (0.5–1.1)e 0.85 (0.7–1.0)
IDNT 1148 3.0 1.06 (0.5–2.1) 0.94 (0.6–1.6)g 0.80 (0.6–1.1)
RENAAL 1513 1.3 0.95 (0.6–1.4) 0.73 (0.5–1.1)g 0.68 (0.5–0.9)
SCOPE 4937 3.2 0.76 (0.6–1.0) 1.11 (0.8–1.6) NA
Val–HEFT 5010 5.2 NA 1.01 (0.8–1.2)h 0.72 (0.6–0.8)i
ARB versus diuretic/beta-blocker
LIFE 9193 1.1 0.74 (0.6–0.9) 0.99 (0.8–1.2) 0.95 (0.8–1.2)
ARB versus calcium antagonist
IDNT 1146 1.0 1.87 (0.9–3.9) 1.64 (0.9–2.9) 0.59 (0.4–0.8)
VALUE 14 400 2.2 1.14 (1.0–1.3) 1.18 (1.0–1.4) 0.87 (0.8–1.0)
ARB versus ACEI trials
ELITE II 3152 NS 1.64 (0.8–3.5)c 1.27 (1.0–1.6)f 0.86 (0.6–1.3)i
OPTIMAAL 5477 0.1 1.06 (0.8–1.4) 1.10 (1.0–1.2) 1.16 (0.9–1.4)
VALIANT 9818 1.1 0.94 (0.8–1.2) 0.96 (0.9–1.1) 1.01 (0.9–1.1)
ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker, CHD, coronary heart disease; CI, confidence interval; NS, not significantly different from
zero at 5%; SBP, systolic blood pressure. a Only participants assigned to single drug therapy comparison (ACEI versus placebo but not ACEI plus diuretic versus placebo)
included. b Difference in follow-up blood pressure levels between randomized groups calculated by subtracting level in first listed treatment group from level in second listed
treatment group. c Non-fatal strokes not included. d Fatal myocardial infarction and sudden death not included. e Includes fatal cardiovascular events in addition to fatal
myocardial infarction and sudden cardiac death. f Non-fatal myocardial not included. g Sudden cardiac death not included. h Fatal and non-fatal myocardial infarction not
included. i Non-fatal heart failure not included.participants was 67 years and 58% were men. In both
sets of trials, the majority of participants were white
Caucasian.
Blood pressure effects
For trials of both ACEI and ARB, the magnitude of the
risk reduction achieved for stroke, CHD and heart failure
was positively associated with the size of the blood
pressure reduction (Table 2). Treatment with ACEI-
based regimens achieved a 19% reduction in the risk
of stroke, a 16% reduction in the risk of CHD and a 27%
reduction in the risk of heart failure for each 5 mmHg
reduction in blood pressure. The corresponding
reductions in the risk for ARB were 26, 17 and 12%
respectively, although the confidence limits around theseopyright © Lippincott Williams & Wilkins. Unauthestimates were wider than for ACEI as a result of the
smaller number of patients studied.
Blood pressure-independent effects
For CHD, there was evidence that ACEI provided pro-
tection that was greater than that which could be attrib-
uted to the blood pressure differences observed. At zero
blood pressure reduction, the estimated relative risk
reduction for CHD was 9% (3 to 14%, P¼ 0.004;
Table 2). There was no such effect apparent for stroke
(P¼ 0.8) or heart failure (P¼ 0.3). For no outcome was
there evidence that ARB conferred any additional protec-
tion beyond that conferred by blood pressure reduction
alone, although confidence intervals about these estimates
were again wider than for the analyses of ACEI (Table 2).orized reproduction of this article is prohibited.
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Table 2 Estimates of effect attributable to blood pressure and blood pressure-independent effects of angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers
Outcome
ACEI-based regimens
vs other regimen
ARB-based regimen
vs other regimen
P value for
no difference in
effect between ACEI
and ARB-based regimens
Blood pressure effect (OR reduction
and 95% CI for 5 mmHg lower blood pressure)
Stroke 19 (2.33) 26 (12.51) 0.6
CHD 16 (7.25) 17 (29.47) 0.7
Heart failurea 27 (13.39) 12 (41.45) 0.3
Blood pressure-independent effect (OR reduction
and 95% CI at zero blood pressure reduction)
Stroke 2 (13.8) 1 (20.18) 0.6
CHD 9 (3.14) 8 (39.17) 0.002
Heart failurea 5 (5.15) 17 (12.38) 0.6
ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker, CHD, coronary heart disease; CI, confidence interval; OR, odds ratio. The effect
estimates and confidence intervals are odds ratios (and 95% confidence intervals) for each 5 mmHg lower blood pressure and the relative risk (and 95% confidence
interval) at zero blood pressure reduction. The null hypothesis of no difference between the two drug classes in either their blood pressure effect or their effect independent
of blood pressure is the P value. a ACEI and ARB trials in which calcium antagonists were a comparator arm were excluded from the primary analyses of the outcome heart
failure (see Methods).Sensitivity analyses
For the outcomes of stroke and CHD, the sensitivity
analyses did not provide any evidence to indicate that
the observed blood pressure-dependent and independent
effects were in any way determined by the composition of
the comparator treatment regimen. For the outcome of
heart failure, however, the inclusion of trials with a calcium
antagonist comparator arm indicated that with zero blood
pressure reduction there was a borderline 10% (0 to 19%,
P¼ 0.06) reduction in heart failure risk with ACEI treat-
ment and an 18% (9 to 27%, P¼ 0.001) reduction with
ARB. These effects were not apparent in the trials that
involved other comparator regimens. Given the known
limitations of calcium antagonists in preventing heart
failure, this finding suggests a blood pressure-independent
adverse effect of calcium antagonists rather than a
blood pressure-independent protective effect of ACEI
or ARB.
Comparisons of angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers
Indirect comparison
The blood pressure-dependent and independent effects
of ACEI and ARB on each outcome were compared to
examine whether there was evidence of a difference
between the two drug classes. The association between
the magnitude of reduction in blood pressure and the size
of relative risk reduction for stroke, CHD and heart
failure were similar for ACEI and ARB (all P> 0.2;
Table 2). There was also no evidence that ACEI and
ARB were different to each other in terms of their like-
lihood of providing protection independent of blood
pressure lowering for stroke or heart failure (both
P¼ 0.6). A single combined regression of ACEI and
ARB trials was therefore calculated for stroke and heart
failure (Fig. 1). There was, however, evidence (P¼ 0.002)
of a difference between ACEI and ARB for CHD,
suggesting greater protection independent of blood
pressure lowering with ACEI than ARB (Table 2,
Fig. 1).opyright © Lippincott Williams & Wilkins. UnauthoDirect comparison
The effects of ACEI and ARB were directly compared in
the supplementary meta-analysis of three head-to-head
trials [3,4,37], collectively including 18 447 individuals
with acute myocardial infarction or heart failure, or both
(Table 1). In those studies, the mean age of participants
was 67 years and 70% were men. A total of 6181 major
cardiovascular events contributed to the analyses. There
was an estimated mean 0.7 mmHg lower follow-up
systolic blood pressure in the ARB group compared
with the ACEI group. The meta-analyses identified no
differences between these two drug classes for any of
the three outcomes (Fig. 2), but confidence limits were
wide and could not exclude true differences of moderate
magnitude.
Discussion
The primary analyses, based on the findings from 26
major trials comparing ACEI or ARB with other com-
parators, show that the size of blood pressure reduction
achieved with either drug class is directly associated with
the size of the reductions in the risk of stroke, CHD and
heart failure. In addition, the analyses also show that for
CHD, treatment with an ACEI provides an additional 9%
relative risk reduction beyond that explained by the
observed blood pressure differences. Although no such
effect was observed for ARB, the confidence limits were
too wide to exclude a modest effect. There was, however,
evidence that this cardioprotective effect of ACEI was
significantly greater than any such effect produced by
ARB. No similar blood pressure-independent effect was
observed for stroke or heart failure for either drug class.
A supplementary meta-analysis involving data from three
trials that directly compared an ACEI and an ARB in
patients with acute myocardial infarction or heart failure
did not detect a difference between these regimens for
any outcome. The confidence limits for each estimate of
treatment difference were, however, wide and did not
exclude the possible existence of a difference in CHDrized reproduction of this article is prohibited.
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Fig. 1
Associations of blood pressure reduction with risk reduction for stroke,
coronary heart disease, and heart failure in trials of angiotensin-
converting enzyme inhibitors (ACEI) and angiotensin receptor blockers
(ARB). Blue circles represent trials of ACEI and black circles represent
trials of ARB with the area of each circle inversely proportional to the
variance of the log odds ratio. Fitted lines represent the summary
meta-regressions for each outcome. ACEI and ARB trials in which
calcium antagonists were a comparator arm were excluded from the
primary analyses of the outcome heart failure (see Methods).
Fig. 2
Meta-analysis of trials directly comparing angiotensin-converting
enzyme inhibitor (ACEI) with angiotensin receptor blocker (ARB)-based
regimens for the outcomes of stroke, coronary heart disease (CHD) and
heart failure. Boxes and horizontal lines represent relative risk and 95%
confidence interval (CI) for each trial. The size of each box is
proportional to the inverse of variance of that trial result. Diamonds
represent the overall estimate of effect calculated using a random
effects inverse variance-weighted method. The width of the diamond
represents the 95% CI, and the centre the point estimate of relative risk.risk of the magnitude suggested by the primary analyses.
The confidence limits for coronary disease were consist-
ent with as much as a 19% lower risk, as well as a 6%
greater risk, among those assigned the ACEI. Further-
more, patients with heart failure or acute myocardial
infarction may respond differently to ACEI and ARB
compared with patients selected on the basis of high
blood pressure and an elevated cardiovascular risk (who
made up the majority of the population in the trials
contributing to the meta-regressions).
These findings extend those previously reported by the
Collaboration in the second cycle of overviews [1]. Those
overviews showed that blood pressure was a major com-
ponent of the benefit conferred by a range of commonly
used blood pressure-lowering regimens. Those analyses
were, however, unable to detect or refute any plausibly
modest independent effects of ACEI or ARB on any
cause-specific cardiovascular outcome. The present
analyses provide much more reliable information about
the blood pressure-dependent and independent effects
of ACEI and ARB for two main reasons: first, the analyses
include nine new ACEI and ARB trials with data from
an additional 48 745 patients; and second, they involve
more sophisticated statistical methods specifically aimed
at the identification of blood pressure-dependent and
independent components of the treatment effects.
The main potential limitation of these analyses is that
indirect comparisons between the effects of ACEI andorized reproduction of this article is prohibited.
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parator drug regimens. A series of sensitivity analyses did
not suggest that the inclusion or exclusion of trials with
a particular comparator treatment regimen produced
results substantially different from the main findings
for stroke and CHD. In addition, exclusion of the HOPE
trial, about which there has been some controversy [39]
also had no material effect on the conclusions. For heart
failure, in which the effect estimates were systematically
altered by the inclusion of the trials that included a
calcium antagonist comparator, the results of the sensi-
tivity analyses were consistent for both ACEI and ARB,
and appeared to reflect the known limitations of calcium
antagonists in preventing heart failure [1].
In conclusion, these analyses confirm that the size of the
reduction in blood pressure achieved with either ACEI or
ARB is a major determinant of the size of the reductions
in coronary disease, stroke and heart failure risks. In
addition, these analyses have identified a potentially
important blood pressure-independent protective effect
of ACEI on the risk of CHD. In particular, there was clear
evidence of protection against coronary disease with
ACEI even in the absence of any reduction in blood
pressure. This blood pressure-independent effect was
equivalent to the estimated effect of an additional
3 mmHg reduction in systolic blood pressure. These
findings, therefore, suggest that the coronary disease
prevention afforded by a blood pressure-lowering regi-
men may be determined by the choice of agent as well
as the size of the blood pressure reduction achieved.
Maximization of the benefit may therefore be achieved
with a regimen that includes an ACEI together with other
drugs in an effort to optimize the size of the blood
pressure reduction achieved.
These analyses did not detect a blood pressure-indepen-
dent beneficial effect of ARB on coronary disease risk,
although a real effect of modest magnitude could not be
excluded. The results confirm and extend those of other
systematic reviews [40,41], however, which have ques-
tioned the probity of claims that ARB might increase the
risk of CHD [42]. Neither these analyses nor earlier
analyses conducted by the Collaboration [1,43] have
provided any convincing evidence of an adverse effect
of ARB on any major cardiovascular outcome. The obser-
vation of greater blood pressure-independent effects on
coronary disease in the ACEI trials than in ARB trials,
although statistically significant, was neither confirmed
nor refuted by meta-analyses of the trials of head-to-head
comparisons of ACEI and ARB among patients with
acute myocardial infarction or heart failure. These trials
even in combination were, however, too small to detect a
difference reliably of the magnitude suggested by the
primary analyses. An ongoing very large-scale trial [44]
comparing the effects of an ACEI and an ARB (and their
combination) in a broader high-risk patient group willopyright © Lippincott Williams & Wilkins. Unauthotherefore provide important additional information on
this question. In the longer term, studies of direct renin
inhibitors [45] will add an important further dimension to
this field.
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